Clinical uses of anti-Müllerian hormone assays: pitfalls and promises

Streuli, Isabelle; Fraisse, Timothée; Chapron, Charles; Bijaoui, G; Bischof, P.; Ziegler, Dominique de

doi:10.1016/j.fertnstert.2007.10.067

Cited by 91 publications

(67 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is well documented in literature that the stability of AMH levels -even during the menstrual cycle -is debatable and may result in conflicting interpretation [47]. Possible fluctuation may not be related to different AMH assays and hence may account for patient variability [48], hence the variability of AMH in the infertile population merits yet delineation [49]. The possible variability on AMH levels has been reported to be heightened for the "younger" in comparison to the "aging" ovary [50].…”

Section: Discussionmentioning

confidence: 99%

A Case Series on Platelet-Rich Plasma Revolutionary Management of Poor Responder Patients

Sfakianoudis¹,

Simopoulou

Nitsos³

et al. 2018

Gynecol Obstet Invest

View full text Add to dashboard Cite

Poor responders are described as those In Vitro Fertilization (IVF) patients who are failing to respond to controlled ovarian stimulation protocols. Extensive research has focused on crafting the optimal treatment. However, it appears that each approach fails to be established as effective or guaranteed towards successful management. Platelet-Rich Plasma (PRP) is a novel, highly promising approach that has been successfully applied for an array of medical issues. In this case series, we present 3 poor responder patients with the common denominator of: failed IVF attempts, poor oocyte yield, and poor embryo quality. The option of oocyte donation was rejected. All patients were treated with autologous PRP ovarian infusion following written consent. Within a 3-month interval, follicle-stimulating hormone decreased by 67.33%, while Anti-Müllerian hormone increased by 75.18%. These impressive results on the biochemical infertility markers alone are classified as a complete biological paradox, coupled by improved embryo quality. Results report a natural conception at 24 weeks, an uncomplicated healthy pregnancy at 17 weeks and a successful live birth. To our knowledge, this is the first time such an approach and results are reported, where PRP treatment on poor responders lead to overcoming their challenging reproductive barrier.

show abstract

Section: Discussionmentioning

confidence: 99%

A Case Series on Platelet-Rich Plasma Revolutionary Management of Poor Responder Patients

Sfakianoudis¹,

Simopoulou

Nitsos³

et al. 2018

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…AMH inhibits excessive follicular recruitment by FSH and therefore has a critical role in folliculogenesis [17,18] It was previously reported that AMH serum levels do not significantly change throughout the menstrual cycle [19][20][21]. However, recent reports revealed statistically significant cyclical fluctuations in AMH levels with a rapid decrease in AMH levels in the early luteal phase [22,23]. Likewise, AMH level also declines gradually during controlled ovarian stimulation [24].…”

Section: Discussionmentioning

confidence: 99%

Anti-mullerian hormone and cumulative pregnancy outcome in in-vitro fertilization

Kini

Morrell

et al. 2010

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose To evaluate the role of Anti-mullerian hormone (AMH) in predicting cumulative pregnancy outcome during in-vitro fertilization (IVF) treatment. Methods Serum AMH levels on day 6 of ovarian stimulation were taken from 180 women undergoing IVF with or without intracytoplasmic sperm injection (ICSI). The main outcome measures were ongoing pregnancy in the fresh cycle, cumulative ongoing pregnancy and ovarian response.Results There was a trend of higher median AMH levels in subjects achieving ongoing pregnancy in the fresh IVF cycle. The median AMH levels were significantly higher in subjects attaining ongoing pregnancy cumulatively and in subjects showing ovarian hyper-response in the stimulated cycle. Areas under the ROC curves were 0.606 and 0.792 for the prediction of cumulative ongoing pregnancy and ovarian hyper-response respectively. Conclusions Serum AMH concentration on day 6 of stimulation was significantly higher in subjects who achieved cumulative ongoing pregnancy in IVF compared to those who did not. Serum AMH is a reasonably good predictor of ovarian hyper-response.

show abstract

“…The fluctuations observed were smaller than intercycle variability and, therefore, were not clinically relevant as far as AMH measurement for clinical purposes were concerned. They suggested that in daily practice, AMH could be measured any time during the menstrual cycle [35].…”

Section: Discussionmentioning

confidence: 99%

Prediction of high ovarian response to controlled ovarian hyperstimulation: anti-Müllerian hormone versus small antral follicle count (2–6 mm)

Aflatoonian

Oskouian

Ahmadi

et al. 2009

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose To evaluate the predictive value of basal serum anti-müllerian hormone level and small antral follicle count for high ovarian response to controlled ovarian hyperstimulation. Methods A total of 159 patients were prospectively included. Basal serum anti-müllerian hormone and small antral follicle count (2-6 mm) were measured. Results Small antral follicle count and anti-müllerian hormone have similar predictive accuracy for high ovarian response with area under curve of 0.961 and 0.922, respectively. The sensitivity and specificity for prediction of high ovarian response were 89% and 92% for small antral follicle count and 93% and 78% for anti-müllerian hormone at the cutoff values of ≥ 16 and ≥ 34.5 pmol/l, respectively. Conclusions Small antral follicle count and anti-müllerian hormone are equally accurate predictors of high ovarian response and facilitate determination of the optimal strategy for controlled ovarian hyperstimulation.

show abstract

Clinical uses of anti-Müllerian hormone assays: pitfalls and promises

Cited by 91 publications

References 18 publications

A Case Series on Platelet-Rich Plasma Revolutionary Management of Poor Responder Patients

A Case Series on Platelet-Rich Plasma Revolutionary Management of Poor Responder Patients

Anti-mullerian hormone and cumulative pregnancy outcome in in-vitro fertilization

Prediction of high ovarian response to controlled ovarian hyperstimulation: anti-Müllerian hormone versus small antral follicle count (2–6 mm)

Contact Info

Product

Resources

About